Enveric Reports Q2 Loss of $3.0M, $8.3M Cash, and $6.5M in New Financing
ENVB sits 23% above its 52-week low of $1.25 on light trading volume (0.3× avg).
Summary
Enveric reported a $3.0M Q2 net loss with $8.3M cash on hand, and disclosed $6.5M in new financing from a private placement and warrant exercises.
Key Events · Earnings and Guidance · ENVB
-
Q2 Net Loss Widens
Net loss attributable to stockholders was $3.0 million for Q2 2026, up from $2.5 million in Q2 2025. Loss per share improved to $0.76 from $11.65 due to the reverse split.
-
Cash Position at $8.3M
Cash-on-hand was $8.3 million as of June 30, 2026, providing limited runway given the going concern warning and ongoing operating losses.
-
New Financing Totals $6.5M
Closed a private placement for approximately $5.0 million in upfront gross proceeds, with potential for up to $8.9 million more if warrants are exercised. Raised an additional $1.5 million from warrant exercises.
-
IP Portfolio Strengthened
Received a USPTO Notice of Allowance for the EVM401 Series and secured U.S. Patent No. 12,605,361 for the EVM301 Series, expanding protection around neuroplastogen candidates.
Analysis · ENVB · Life Sciences
The second quarter saw Enveric's net loss widen to $3.0 million from $2.5 million a year earlier, though the per-share loss improved sharply to $0.76 from $11.65 thanks to the reverse split. With only $8.3 million in cash at quarter-end, the going concern warning looms large. The $5.0 million private placement and $1.5 million in warrant exercises offer near-term runway but come with dilution. Meanwhile, the patent allowance and new patent bolster the IP around EB-003, yet the financial footing remains shaky.
At the time of this filing, ENVB was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $1.25 to $17.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.